5554 studies found for:    "breast cancer"
Show Display Options
Rank Status Study
21 Terminated Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
Conditions: Breast Cancer;   HER2 Positive Breast Cancer;   Metastatic Breast Cancer;   Cancer of the Breast
Interventions: Drug: IPI-504;   Drug: Trastuzumab
22 Recruiting Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
23 Recruiting Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: carboplatin;   Other: fluorine F 18 fluorothymidine;   Procedure: positron emission tomography;   Other: laboratory biomarker analysis;   Other: pharmacological study
24 Active, not recruiting Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: dinaciclib;   Drug: epirubicin hydrochloride;   Other: laboratory biomarker analysis
25 Active, not recruiting Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: AZD2281;   Drug: Paclitaxel
26 Completed A Study of Gemcitabine, Epirubicin, and Paclitaxel Combination Chemotherapy Given Before Surgery to Patients With Locally Advanced Breast Cancer
Conditions: Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IV Breast Cancer;   Breast Cancer;   Locally Advanced
Intervention: Drug: gemcitabine, epirubicin, paclitaxel
27 Active, not recruiting Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Skin Metastases;   Stage IV Breast Cancer
Interventions: Drug: imiquimod;   Drug: Abraxane;   Other: laboratory biomarker analysis;   Genetic: RNA analysis;   Other: immunoenzyme technique
28 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
29 Completed Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer
Conditions: Breast Cancer;   Estrogen Receptor-Positive Breast Cancer;   Breast Cancer, Estrogen Receptor-Positive;   ER+ Breast Cancer
Interventions: Drug: entinostat;   Drug: exemestane
30 Recruiting Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
Conditions: Inflammatory Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
31 Recruiting Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: veliparib;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: pharmacological study;   Other: laboratory biomarker analysis
32 Completed Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer
Conditions: Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Capecitabine
33 Recruiting A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients
Conditions: Taxane-induced Peripheral Neuropathy;   Chemotherapy-induced Peripheral Neuropathy (CIPN);   Early-Stage Breast Carcinoma;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions: Procedure: Immediate Acupuncture Group;   Procedure: Delayed Acupuncture Group
34 Terminated Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors
Conditions: Cancer Survivor;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Intervention: Other: Educational Intervention
35 Completed Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
36 Recruiting BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Conditions: Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: PI3K inhibitor BYL719;   Drug: letrozole;   Other: laboratory biomarker analysis;   Other: pharmacological studies
37 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, And Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Drug: carboplatin;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Other: pharmacological study;   Other: laboratory biomarker analysis
38 Active, not recruiting Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: eribulin mesylate;   Drug: carboplatin;   Procedure: biopsy
39 Active, not recruiting Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasms;   Breast Tumors;   Cancer;   Locally Recurrent and Metastatic Breast Cancer;   Metastases;   Metastatic Cancer;   Oncology;   Solid Tumors;   Tumors
Interventions: Drug: AMG 386 30 mg/kg, Paclitaxel and Trastuzumab;   Drug: AMG 386 30 mg/kg, Capecitabine and Lapatinib;   Drug: AMG 386 10 mgkg, Paclitaxel and Trastuzumab;   Drug: AMG 386 10 mg/kg, Capecitabine and Lapatinib
40 Active, not recruiting Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Drug: cyclophosphamide;   Biological: bevacizumab;   Drug: carboplatin

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years